MADISON, Wis.--(BUSINESS WIRE)--Eight Wisconsin bioscience companies have been selected as the winners of BioForward’s 2013 Emerging Company Showcase. The showcase is part of the 2013 Bioscience Vision Summit, being held on Wednesday, September 18th, at the Monona Terrace Convention Center in Madison, Wis. and hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s bioscience industry. The Emerging Company Showcase is sponsored by the Center for Technology Commercialization-WI Entrepreneurs Network, Exact Sciences, MG&E and UW-Office of Corporate Relations.
Each of these Wisconsin-based early stage companies were chosen because they have transitioned successfully out of research and development, with good proof of concept for their products. Each was judged to have a unique value proposition. This year’s Emerging Company Showcase winners are:
ABL Technologies, LLC
ABL Technologies, LLC has developed a
disruptive mapping technology to help treat Heart Arrhythmias by RF
Ablation procedure. This is a $2.5bil market worldwide, growing at 30%
per year. The safety features embedded in ABL’s technology will make
this the future standard of care in certain Ablation procedures. ABL’s
technology will cost Hospitals 70% less per procedure. EP Physicians
love the ABL technology because it makes RF Ablation a lot safer for the
patient and more efficient for the EP.
Co-D Therapeutics | www.co-dtherapeutics.com
Co-D
Therapeutics, Inc. based in Madison, WI, is an innovative drug
development company dedicated to bringing to market first-in-class,
combination nano-medicines with high safety profiles to treat cancer and
improve patient’s lives. Co-D Therapeutics’ polymeric platform
technology focuses on the formulation and delivery of multiple
anticancer agents in a single novel therapeutic. Co-D Therapeutics is
developing its nano-medicine lead product, Triolimus, to treat the rare
malignancy, angiosarcoma, under an orphan drug designation, breast
cancer and non-small cell lung cancer. Triolimus will replace less
efficacious, less safe, and more complex conventional combination
chemotherapy regimens in clinical practice
Imbed Biosciences | www.imbedbio.com
Imbed
Biosciences Inc. is developing advanced wound care dressings based on
its patent-pending antimicrobial polymeric nanocoatings for medical
devices. The company is introducing a first of its kind wound dressing
that can employ antimicrobial properties of silver at the onset of a
wound treatment without tissue toxicity or irritation. Our first product
is a ‘microfilm wound dressing’ intended for use on burns, donor sites,
surgical wounds, and skin ulcers. The ultrathin dressing conforms to the
micro-contours of the wound-bed, maintains wound moisture, releases
antimicrobial silver for up to 7 days, and ultimately dissolves for
painless removal in wound-debris.
inseRT MRI | http://www.insertmri.com/
inseRT
MRI has recognized key gaps constraining the adoption of minimally
invasive, magnetic resonance (MR) image-guided surgical procedures. We
are developing a platform technology for encapsulating workflow ‘apps’
to interactively guide these procedures. We partner rather than compete
with therapeutic device and scanner manufacturers by providing
customizable imaging solutions that current MR manufacturers are unable
to provide due to technical or market fundamentals. We have two current
focus areas: brain drug delivery and guiding robotic in-bore breast
biopsy through our partners at Marvel Medtech. We provide an FDA
regulatory approval pathway that is independent of the MR scanner
regulatory process.
Microscopy Innovations | www.microscopyinnovations.com
Microscopy
Innovations, LLC, of Marshfield, WI, produces high-impact life science
tools. Its mPrep™ System — an innovative capsule-based system for
microscope sample preparation and efficient “experimentation in a
capsule” — is covered by U.S. and international patents. Over 1 billion
biological specimens are prepared for microscopic analysis annually in
academic, pharmaceutical and clinical laboratories worldwide. But,
current preparation methods are time-consuming, inefficient, and
prone-to-error. The mPrep™ System addresses these problems. Users can
lower total processing costs by an average of 25%, improve turn-around
time, reduce error rates and cut chemical usage and disposal by 75% or
greater.
Regenerative Medical Solutions | http://www.regenmedsolutions.com
Regenerative
Medical Solutions (RMS) is an early stage company that is dedicated to
helping find a cure for diabetes. RMS provides its pancreatic cells,
ProgenMix™, for pharmaceutical companies wishing to utilize these cells
for drug discovery, efficacy and toxicity testing or as cells in
progression toward a therapy. These cells provide an early indicator if
drug candidates can be effective or hazardous and reduce the reliance on
animal models, potentially saving millions of dollars in time and
development costs. RMS’s cells are also derived from induced pluripotent
stem cells (iPSCs), thus avoiding the ethical concerns of embryonic stem
cells. RMS’s intellectual property is derived from co-founder Dr. Jon
Odorico’s extensive work at the University of Wisconsin over the past
decade.
Stealth Therapeutics | www.stealththerapeutics.com
Stealth
Therapeutics was founded in 2006 by Bradley Glenn, MD., a practicing,
board certified Interventional Radiologist. Dr. Glenn founded the
company for the purpose of designing and developing a portfolio of
improved venous access devices (VADS) that would be less invasive and
have the smallest possible impact on the lives of patients. This product
is more convenient and stable than a standard PICC line and is made with
a polyurethane catheter and a titanium septum that is power injectable
to 300psi/5cc/sec. The Invisiport is intended for use with long-term
delivery of medications, nutritional supplementation, fluids, blood,
blood products, the sampling of blood, and for the power injection of
contrast media when used with a power-injectable Huber needle or
infusion set. The Invisiport features a patented self-deploying wing
that minimizes insertion size and supports stability once implanted in
the patients arm or chest.
XenoGen Biosystems | http://xenogenbiosystems.appspot.com/
XenoGen
Biosystems is a software solution to the wide distribution of life
science information. Because life science data is gathered and stored by
project or experiment, building comprehensive biological models and
informatics is extremely laborious. XenoGen software enables
experimental genomic information to be correlated with phenotypes, and
standard reference genomes, wherever the information may reside. At
XenoGen, we focus on data accessibility, correlation, and comprehensive
analysis without disrupting any existing workflow. XenoGen tools put
computational and mathematical power into the hands of life science
researchers.
In addition to complimentary registration for the summit, the winners receive high-visibility exhibit space, recognition at one of the summit’s large plenary sessions, a complimentary year of membership in BioForward, and specialized one-on-one technical assistance ranging from business planning and investor introductions to collaborative partnerships courtesy of the Center for Technology Commercialization-WI Entrepreneurs Network, Exact Sciences, Madison Gas & Electric and UW-Office of Corporate Relations.
“With the continued growth in the Bioscience sector, we are pleased to announce this group of emerging company showcase winners for 2013. These eight companies characterize the diversity and innovation of technology within Wisconsin’s bioscience industry,” said Bryan Z. Renk, Executive Director of BioForward.“BioForward is committed to fostering growth in Wisconsin and these organizations represent key industries that will be at the center of future job creation.”
Registration for the Biotechnology Vision Summit 2013 is available online, with additional information at http://www.bioforward.org/?page=2013VisionSummit
About BioForward
BioForward is the member-driven state association that is the voice of Wisconsin’s bioscience industry. We advocate actively on our members’ behalf to create investment and partnership opportunities, attract and retain the very best people, and support public policy that fosters their continued growth. We also provide member-support services that include networking opportunities through a variety of conferences and events, online resources and group purchasing programs. Our members include bioscience companies, universities, non-profits, service providers, and state, regional economic development groups.
